Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Solomon

Showing results (131-140 of 184) with videos related to

Pageof 19
Sort By:
International Journal of Cancer|January 18, 2014
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcomeAnnette M Lim, Hongdo Do, Richard J Young, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
A Phase 1 and Biodistribution Study of ABT-806i, an <sup>111</sup>In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806Hui K Gan, Matthew Burge, Benjamin Solomon, et al.
The Lancet. Oncology|February 17, 2019
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trialDavid Ball, G Tao Mai, Shalini Vinod, et al.
Cancer Research|August 23, 2015
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated ProdrugsFrancis W Hunter, Richard J Young, Zvi Shalev, et al.
Molecular Cancer Therapeutics|June 15, 2017
Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell CarcinomaClare E Weeden, Aliaksei Z Holik, Richard J Young, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serumJennifer A Westwood, William K Murray, Melanie Trivett, et al.
The Journal of Experimental Medicine|November 13, 2008
Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondiiWendy T Watford, Bruce D Hissong, Lydia R Durant, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2023
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMesoNicholas McNamee, Catriona Harvey, Lauren Gray, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
Pageof 19

Showing results (131-140 of 184) with videos related to

Sort By:
Pageof 19
International Journal of Cancer|January 18, 2014
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcomeAnnette M Lim, Hongdo Do, Richard J Young, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
A Phase 1 and Biodistribution Study of ABT-806i, an <sup>111</sup>In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806Hui K Gan, Matthew Burge, Benjamin Solomon, et al.
The Lancet. Oncology|February 17, 2019
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trialDavid Ball, G Tao Mai, Shalini Vinod, et al.
Cancer Research|August 23, 2015
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated ProdrugsFrancis W Hunter, Richard J Young, Zvi Shalev, et al.
Molecular Cancer Therapeutics|June 15, 2017
Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell CarcinomaClare E Weeden, Aliaksei Z Holik, Richard J Young, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serumJennifer A Westwood, William K Murray, Melanie Trivett, et al.
The Journal of Experimental Medicine|November 13, 2008
Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondiiWendy T Watford, Bruce D Hissong, Lydia R Durant, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2023
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMesoNicholas McNamee, Catriona Harvey, Lauren Gray, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
Pageof 19